Introduction
The use of nanotechnology has resulted in some novel and interesting medical and/or industrial uses, but also probable danger for human and environmental health. [1] [2] [3] Accidental or involuntary contact during production or use of nanoparticles (NPs) may occur via various routes such as inhalation, ingestion, or skin penetration. 3, 4 Actually, the potential of NPs to pass across the alveolar-capillary barrier and to reach the circulating blood and thus have access to other organs is a reason for disquiet. 3, 5 It has been shown that NPs may penetrate the cells and be more biologically active than microsized particles because of their small size and large surface to volume ratio.
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Nemmar et al additive. 7, 8 CeO 2 NPs have been widely used as a diesel fuel additive since 1999, because of their enhanced fuel-burning efficiency and decreased levels of greenhouse gases and particle numbers in vehicle exhaust. 7, [9] [10] [11] However, it has been shown that, along with diesel exhaust particles (DEPs), CeO 2 NPs are emitted in diesel exhaust, resulting in exposure to humans by inhalation. 8 Experimental studies in rodents have shown that acute (1 day) and subacute (28 days) intratracheal (IT) instillation of CeO 2 NPs in rats induced lung inflammation, alveolar macrophage toxicity, air-blood barrier damage, and phospholipidosis. 12, 13 It has also been demonstrated that either acute inhalation or IT instillation of CeO 2 NPs in mice caused pulmonary inflammation and small granulomas. 14, 15 More recently, it has been shown that CeO 2 NPs induce pulmonary fibrosis and that the amorphous silica coating of CeO 2 NPs reduced the inflammation, phospholipidosis, and fibrosis. 16, 17 It is well-established that particulate air pollution and some engineered NPs affect the cardiovascular system either through inflammatory mediators produced in the lungs and released into the circulation or via their ability to cross the alveolar-capillary barrier and reach the cardiovascular system. 5, 18 Since CeO 2 NPs have been shown to cross the alveolar-capillary barrier to reach extrapulmonary sites 19, 20 and cause lung inflammation, 14, 15, 20 the present study hypothesized that these NPs can plausibly interact with the circulating platelets and vasculature and induce thrombotic events. This has not been investigated before, and, consequently, the aim of this study was to assess the acute (24 hours) effect of CeO 2 NPs on pulmonary and systemic inflammation and oxidative stress in mice and to evaluate their effects on coagulation in vivo and in vitro.
Material and methods Particles
CeO 2 NPs, 10%, w/w, in water with an average diameter of ~20 nm, were obtained from Sigma-Aldrich (St Louis, MO, USA). The CeO 2 NP samples were diluted in sterile saline (0.9% NaCl). To minimize aggregation, particle suspensions were sonicated for 5 minutes in a Clifton ultrasonic bath (Clifton, NJ, USA) before dilution and IT administration. Particle suspensions were prepared immediately before use and were vigorously vortexed to obtain a well-mixed suspension prior to each instillation. The same particles from the same source were characterized and used recently by Ma et al. 12, 21 animals and IT instillation This project was reviewed and approved by the Institutional Review Board of the United Arab Emirates University, College of Medicine and Health Sciences, and the experiments were performed in accordance with the protocols approved by the Institutional Animal Care and Research Advisory Committee.
Both male and female BALB/c mice (Taconic Farms Inc., Germantown, NY, USA) weighing 23±2 g were housed in light-(12-hour light:12-hour dark cycle) and temperaturecontrolled (22°C ±1°C) rooms. The animals had free access to tap water and commercial laboratory chow.
Mice were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and placed supine with extended neck on an angled board. A Becton Dickinson (Sparks, MD, USA) 24-gauge cannula was inserted via the mouth into the trachea. Either CeO 2 NP suspensions (0.1 or 0.5 mg/kg) or saline only were instilled IT (0.1 mL) via a sterile syringe, followed by an air bolus of 0.1 mL.
Blood collection and bronchoalveolar lavage (BAL) fluid analysis
Twenty-four hours after the IT administration of either CeO 2 NPs or saline, the mice were anesthetized as described earlier, and blood was drawn from the inferior vena cava in ethylenediaminetetraacetic acid (4%). The collected blood was centrifuged at 4°C for 15 minutes at 900× g, and the plasma samples were stored at -80°C pending analysis.
Mice were then sacrificed with an overdose of sodium pentobarbital. The trachea was cannulated and the left bronchus was clamped. The right bronchi and right lungs were lavaged three times with 0.7 mL of sterile saline (NaCl 0.9%). The recovered fluid aliquots were pooled. No difference in the volume of collected fluid was observed between the different groups. BAL fluid was centrifuged (1,000× g ×10 minutes, 4°C). Cells were counted in a Thoma hemocytometer after resuspension of the pellets and staining with 1% gentian violet. The cell differentials (n=6-8 per group) were microscopically determined on cytocentrifuge preparations fixed in methanol and stained with Diff Quick (Dade, Brussels, Belgium). The supernatant was stored at -80°C until further analysis.
histopathology
The unlavaged left lungs obtained from the animals above (n=6-8 per group) were fixed with 10% buffered formalin, excised, washed with ice-cold saline, blotted with filter paper, and weighed. Each left lung was sectioned, put in a cassette, and dehydrated in increasing concentrations of ethanol, cleared with xylene, and embedded in paraffin. Sections of 3 μm were prepared from paraffin blocks and stained with hematoxylin and eosin. 22, 23 The stained sections were In plasma (n=6-8 per group), besides measuring TNFα level and catalase activity as described earlier, the levels of CRP (GenWay Biotech, Inc., San Diego, CA, USA), fibrinogen (Molecular Innovation, Southfield, MI, USA), and PAI-1 (Molecular Innovation) were measured by using ELISA kits. The total antioxidant activity was quantified with a colorimetric assay kit (Cayman Chemicals, Ann Arbor, MI, USA).
experimental pial cerebral arteriole thrombosis model
In a separate experiment (n=6-8 per group), in vivo pial arteriolar and venular thrombogenesis was assessed 24 hours after IT instillation of either CeO 2 NPs or saline according to a previously described technique. [24] [25] [26] [27] In vitro platelet aggregation in mouse whole blood
The platelet aggregation assay in whole blood (n=4-6 per group) was performed as described in previous studies. 28, 29 After anesthesia, blood from untreated mice was withdrawn from the inferior vena cava and placed in citrate (3.2%), and 0.1 mL aliquots were added to the well of a Merlin coagulometer (MC 1 VET; Merlin, Lemgo, Germany). The blood samples were incubated at 37°C with either saline (control) or CeO 2 NPs (1, 5, or 25 μg/mL) for 3 minutes and then stirred for another 3 minutes. At the end of this period, 0.025 mL samples were removed and fixed on ice in 225 mL cellFix (Becton Dickinson). After fixation, single platelets were counted in a VET ABX Micros with a mouse card (ABX, Montpellier, France). The degree of platelet aggregation following CeO 2 NP exposure was calculated as a fall in the number of single platelets counted and expressed as a % of control (saline-treated blood). 27 In vitro measurement of prothrombin time (PT) and activated partial thromboplastin time (aPTT) After anesthesia, blood from untreated mice was withdrawn, as described earlier. The PT was measured on freshly collected, platelet-poor plasma with human, relipidated, recombinant thromboplastin (Recombiplastin; Instrumentation Laboratory, Orangeburg, NY, USA) in combination with an MC 1 VET (Merlin). Briefly, the plasma (n=4-6 per group) was incubated for 3 minutes at 37°C. After that, either CeO 2 NPs (1, 5, or 25 μg/mL) or saline (control) was added for another 3 minutes, and then PT was measured as previously described. 25, 30, 31 The aPTT was measured with automated aPTT reagent (BioMerieux, Durham, NC, USA) by using an MC 1 VET (Merlin). Briefly, the plasma (n=4-6 per group) was incubated for 3 minutes at 37°C. After that, either CeO 2 NPs (1, 5, or 25 μg/mL) or saline (control) was added for another 3 minutes, and then aPTT was measured as previously described. 25, 30, 31 Normal plasma was used as reference for both the PT and aPTT.
statistics
All statistical analyses were performed with GraphPad Prism Software version 5 (San Diego, CA, USA). To determine whether parameters were normally distributed, the KolmogorovSmirnov statistic normality test was applied. Comparisons between groups were performed by one-way analysis of variance (ANOVA), followed by Newman-Keuls multiple range tests. Polymorphonuclear neutrophils (PMNs) in BAL fluid and TNFα in BAL fluid and plasma, which were not normally distributed, were analyzed with the Kruskal-Wallis test, followed by Dunn's multiple comparison test. P-values ,0.05 were considered as significant. All the data in the figures were expressed as mean ± standard error of the mean.
Results
effect of ceO 2 NPs on lung histology
Histological sections from lungs of control mice had normal appearance ( Figure 1A-D) . In mice exposed to 0.1 mg/kg CeO 2 NPs, particles were found inside the alveolar macrophages ( Figure 1E and G) as well as within alveolar air spaces ( Figure 1F ). Particles were also seen within the alveolar interstitial space ( Figure 1F ). There was focal damage of the alveolar wall and foci of expansion of the alveolar interstitial space due to neutrophil and macrophage infiltration of the interstitium ( Figure 1G and H). In the group IT instilled with 0.5 mg/kg CeO 2 NPs, particles were also found engulfed by alveolar macrophages ( Figure 1L led to a PMN influx at 0.1 mg/kg (61%±10%, P,0.01) and at 0.5 mg/kg (57%±9%, P,0.01).
effect of ceO 2 NPs on TNFα concentration and catalase activity in BAL fluid
As shown in Figure 3A , compared with the control group, the IT instillation of CeO 2 NPs induced significant increases in TNFα concentrations in BAL fluid at 0.1 and 0.5 mg/kg (P,0.05). On the contrary, IT instillation of CeO 2 NPs caused a significant decrease of catalase activity in BAL fluid at 0.1 mg/kg (P,0.05) and 0.5 mg/kg (P,0.05) compared with the saline-treated group ( Figure 3B ). effect in plasma of ceO 2 NPs on concentrations of crP and TNFα, catalase activity, and antioxidant capacity Pulmonary exposure to CeO 2 NPs induced a slight but a statistically significant increase in CRP concentration at 0.1 mg/kg (P,0.001) and 0.5 mg/kg (P,0.001) compared with the control group ( Figure 4A ). TNFα was dose dependently increased by CeO 2 NPs, but the level of significance was only achieved at 0.5 mg/kg (P,0.05) ( Figure 4B ). On the other hand, compared with the control group, catalase activity was significantly decreased by the 0.5 mg/kg dose (P,0.01) ( Figure 4C ), whereas both doses of CeO 2 NPs induced a significant decrease (P,0.05) of total antioxidant capacity ( Figure 4D ). Figure 5A illustrates that the pulmonary exposure to CeO 2 NPs induced a significant (P,0.001) and dose-dependent shortening of the thrombotic occlusion time in pial arterioles in photochemically injured vessels. Similarly, in pial venules, CeO 2 NP administration caused a dose-dependent and significant (P,0.001) shortening of the thrombotic occlusion time compared with the saline-treated group. effect of ceO 2 NPs on fibrinogen and PaI-1 concentrations in plasma Figure 6A shows that the IT instillation of CeO 2 NPs induced a dose-dependent and significant increase of fibrinogen at doses of 0.1 mg/kg (P,0.001) and 0.5 mg/kg (P,0.001) compared with the control group. The concentration of PAI-1 was, in the same way, increased by the IT instillation of CeO 2 NPs at 0.1 mg/kg (P,0.01) and 0.5 mg/kg (P,0.001) compared with the control group. effect of ceO 2 NPs on platelet aggregation in vitro in whole blood, PT, and aPTT Figure 7 shows that the direct addition of various concentrations of CeO 2 NPs (1-25 μg/mL) to untreated whole blood in vitro did not induce any platelet aggregation. Also, compared with the control group, the incubation of untreated plasma with CeO 2 NPs (1-25 μg/mL) neither altered the PT ( Figure 7B ) nor the aPTT ( Figure 7C ).
effect of ceO 2 NPs on pial arteriole and venule thrombosis
Discussion
In this work, a histological analysis of the lung 24 hours after the IT instillation of CeO 2 NPs revealed an expansion of the alveolar interstitial space due to infiltration of neutrophils and macrophages into the interstitium; particles were also seen within macrophages, and others were found within the alveolar interstitial space. BAL fluid analysis confirmed the influx of neutrophils and an increase of TNFα concentration and decrease in catalase activity. Likewise, in the plasma, the concentrations of CRP and TNFα were increased, whereas the activities of catalase and total antioxidant capacity were 
Figure 7
In vitro platelet aggregation in whole blood (A), prothrombin time (PT) (B), and activated partial thromboplastin time (aPTT) (C) after incubation with either saline or cerium oxide nanoparticles (ceO 2 NPs, 1, 5, or 25 μg/ml). Data are mean ± standard error of the mean (n=4-6 in each group). considered a valid, yet admittedly not perfect, mode of exposure to foreign compounds. 32, 33 The exact dose delivered to the lungs of each mouse can be established precisely, and this technique is simpler than inhalation, thus allowing the introduction of a range of doses to the lung in a short time. 32, 33 Moreover, IT instillation provides more accurate dosing, given that mice are nose breathers that filter most inhaled particles. 32, 33 The doses of particles used in the present study are comparable with those employed in previous animal models of IT administration of CeO 2 NPs. 12, 34 In a previous study, it has been demonstrated that acute 
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Nemmar et al of cardiovascular homeostasis. 5, 29 This is in agreement with clinical and epidemiological studies that reported the development of myocardial complications within 24 hours of exposure to elevated levels of particulate air pollution, 35 and hence, the effect of CeO 2 NPs 24-hour postexposure was assessed. Moreover, this time point is identical to the one used recently to assess the role of mast cells in vascular reactivity and ischemia reperfusion injury following IT administration of CeO 2 NPs. 34 These data show that acute administration of CeO 2 NPs caused a dose-dependent infiltration of neutrophils and macrophages, which caused an expansion of the alveolar interstitial space. Some CeO 2 NPs were engulfed by macrophages, and others gained access to the interstitium. BAL fluid analysis confirmed the latter finding, showing a significant increase in neutrophils after the IT instillation of both doses of CeO 2 NPs. Moreover, a significant and dose-dependent increase in the concentration of TNFα and a decrease in the activity of catalase were found, suggestive of a depletion of this antioxidant. These findings indicate the development of pulmonary inflammation and oxidative stress following acute exposure to CeO 2 NPs. These results corroborate earlier findings which showed an induction of inflammation, cytotoxicity, and air-blood barrier damage, 24-hour post-IT instillation of CeO 2 NPs in rats. 12 The findings of this study are also in agreement with previous studies that demonstrated an increase in neutrophil numbers in BAL fluid and the concentration of cytokine-induced neutrophil chemoattractant (CINC)-1, CINC-2, chemokine for neutrophil, and heme oxygenase-1, 3 days after the IT instillation of either 0.2 mg or 1 mg CeO 2 NPs in rats, which persisted for up to 3 months postexposure. 36 Comparable findings were obtained, in the same study, following inhalation of CeO 2 NPs (2 or 10 mg/m 3 ) for 4 weeks (6 hours per day, 5 days per week). 36 Previous reports showed that pulmonary exposure to pollutant particles and some engineered NPs induce systemic and cardiovascular events. 22, 24, 37, 38 The latter effects were explained by the capacity of NPs to induce lung inflammation, which causes systemic inflammation and oxidative stress, and/or the aptitude of NPs to traverse the air-blood barrier to enter the blood and affect cardiovascular endpoints. 5, 18 It has been reported that IV administration of CeO 2 NPs induce liver injury and oxidative stress. 39, 40 More recently, it has been shown that pulmonary, IV, and gastric exposures to CeO 2 NPs cause endothelium-dependent and -independent arteriolar dysfunction. 20, 41 Nevertheless, the systemic effects of CeO 2 NPs following pulmonary exposure are not fully understood, particularly their possible impact on thrombosis. The data of the present study show a significant increase in CRP caused by both doses of NPs. Moreover, a dose-dependent increase in TNFα concentrations and a decrease in catalase and total antioxidant activities following the acute exposure to CeO 2 NPs were observed. It has been shown that exposure to particulate air pollution increases pulmonary inflammatory mediators that translocate to the circulation, contributing to systemic inflammation, with downstream effects such as cardiovascular dysfunction. 42 It has been shown that IT instillation of DEPs induces lung inflammation and oxidative stress responsible for systemic inflammation and oxidative stress at the 18-24-hour time point. 24, 37 It has been recently demonstrated that aortic RNA expression of endothelial nitric oxide synthase, tissue factor, and TNFα were significantly increased by 4-week inhalation exposure to whole CeO 2 NPs added to diesel fuel (DECe) or gas-phase components of DECe. 19 However, the latter results are in conflict with the data from another study which implied that the addition of a Ce-based fuel-borne catalyst may decrease the atherosclerotic burden induced by exposure to diesel fuel in atherosclerosis-prone mice. 43 Also, it has been shown that CeO 2 NPs improve microvascular reactivity in hypertensive rats. 44 This study evaluated the impact of CeO 2 NPs on coagulation by measuring a set of relevant endpoints, ie, thrombosis in pial arterioles and venules in vivo and measurement of plasma concentrations of fibrinogen and PAI-1 and in vitro platelet aggregation, PT, and aPTT. As far as we are aware, the effect of CeO 2 NPs on an animal model of thrombosis in vivo has not been reported so far. The present study used a well-established model of photochemical-induced thrombosis in pial arterioles and venules. 27, 37, 45 In this model, the damage to endothelial cells causes the platelets to adhere at the site of endothelial damage and then aggregate. 27, 37, 45 The data of the present study show that acute IT administration of CeO 2 NPs induced a significant and dose-dependent shortening of the thrombotic occlusion time in pial arterioles and venules, indicating that CeO 2 NPs possess prothrombotic effects. Along with thrombosis in vivo, a dose-dependent and significant increase in the concentrations of the coagulation factor, fibrinogen, and PAI-1 in the plasma following acute exposure to CeO 2 NPs was found. PAI-1 is a potent endogenous inhibitor of fibrinolysis and has been reported to increase following exposure to DEPs, silica NPs, and carbon nanotubes. [46] [47] [48] It has been shown that a 4-week inhalation exposure to DECe in rats induced an increase of tissue factor, but not in PAI-1 concentration. 19 The discrepancy between the latter study showing the absence of an increase of PAI-1 
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acute pulmonary and thrombotic effects of cerium oxide nanoparticles and this study could be related to the duration of exposure (24 hours versus 4 weeks), mode of exposure (IT instillation versus inhalation), or experimental animals used (mice versus rats). Additional studies are needed to clarify this point.
Recent studies have reported that pulmonary exposure to CeO 2 NPs either by IT instillation or by inhalation resulted in systemic translocation and accumulation in various major organs such as the liver. 19, 49 This study wanted to verify whether the CeO 2 NPs can directly induce platelet aggregation and affect PT and aPTT in vitro. The concentration of 1 μg/mL CeO 2 NPs used here in vitro is similar to that employed recently to induce prothrombotic effects of DEPs in vitro. 29, 50 In addition to the latter concentration, two higher concentrations, that is, 5 and 25 μg/mL CeO 2 NPs were used. These data show that CeO 2 NPs (1-25 μg/mL) neither caused platelet aggregation nor affected either PT or aPTT. The latter findings suggest that the prothrombotic effects of CeO 2 NPs observed in vivo may have resulted from systemic inflammation and oxidative stress rather than the direct contact of CeO 2 NPs with platelets. These results also indicate that the in vitro effects of CeO 2 NPs are different from those of DEPs reported previously, which showed that DEPs induced platelet aggregation in vitro and shortened PT and aPTT. 29, 51 These study data highlight the importance of conducting in vivo toxicity studies with NPs and suggest that the absence of toxicity of NPs in vitro does not necessarily mean that they are devoid of in vivo adverse effects.
This study has limitations. It did not thoroughly study the mechanisms underlying the systemic effects of CeO 2 NPs and has investigated only the acute effects of these NPs. Further studies are warranted to assess the time effects (subacute and chronic) and the possible mechanism underlying the pulmonary and systemic effects of CeO 2 NPs.
In conclusion, the data of this study provide novel evidence that pulmonary exposure to CeO 2 NPs induces pulmonary and systemic inflammation and oxidative stress and promotes thrombosis in vivo.
